<SEC-DOCUMENT>0001193125-24-099057.txt : 20240417
<SEC-HEADER>0001193125-24-099057.hdr.sgml : 20240417
<ACCEPTANCE-DATETIME>20240417160203
ACCESSION NUMBER:		0001193125-24-099057
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240417
DATE AS OF CHANGE:		20240417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275445
		FILM NUMBER:		24850947

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d819343d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration Number 333-275445 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus Dated January&nbsp;31, 2024) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g819343g94r84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>2,536,258 shares of common stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pre-funded warrants to purchase up to 2,135,477 shares of common stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 2,536,258 shares of our common stock, par value $0.001 per share and, in lieu of common stock to investors who so choose, pre-funded warrants
to purchase up to 2,135,477 shares of our common stock. The purchase price of each pre-funded warrant will be equal to the price per share at which shares of common stock are being sold in this offering, minus $0.001. Each pre-funded warrant will be
immediately exercisable for one share of common stock, subject to the limitations described in the section &#147;Description of the Pre-Funded Warrants&#151;Exercisability&#148;, and the exercise price of each pre-funded warrant equals $0.001 per
share. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of the pre-funded warrants. The public offering price for each share of common stock is $7.693 and the public offering price for each
pre-funded warrant is $7.692. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;INO.&#148; On April&nbsp;15, 2024, the last
reported sale price of our common stock on the Nasdaq Capital Market was $10.99<U></U> per share. There is no established public trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to list the
pre-funded warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a
&#147;smaller reporting company&#148; under applicable Securities and Exchange Commission rules and are subject to reduced public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being a Smaller Reporting
Company.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.69300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$7.69200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,937,521.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.46158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$0.46152</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156,251.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.23142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$7.23048</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,781,270.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:12.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:24%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; beginning on page <FONT STYLE="white-space:nowrap">S-25</FONT>
of this prospectus supplement for additional information regarding total underwriting compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities
involves risk. See &#147;<A HREF="#supprom821461_4">Risk Factors</A>&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-7</FONT> of this prospectus supplement, on page&nbsp;7 of the accompanying base prospectus and in our filings with
the Securities Exchange Commission, or the SEC, that are incorporated by reference herein and therein to read about factors you should consider before investing in our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the
shares of common stock and pre-funded warrants against payment on or about April&nbsp;18, 2024. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint
Bookrunning Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="bottom"><B>Oppenheimer&nbsp;&amp; Co.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Citizens JMP</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus supplement is April&nbsp;15, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom819343_8b">DESCRIPTION OF THE PRE-FUNDED WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_8a">CAPITALIZATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_9">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF OUR COMMON STOCK
 AND PRE-FUNDED WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_10">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom821461_14">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>PROSPECTUS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we have filed with the Securities and Exchange Commission, or the SEC, utilizing a shelf
registration process. This prospectus supplement is not complete without, and may not be utilized except in connection with, the accompanying prospectus. This prospectus supplement provides supplemental information regarding us and updates certain
information contained in the accompanying prospectus and describes the specific terms of this offering. The accompanying prospectus gives more general information, some of which may not apply to this offering. We incorporate important information
into this prospectus supplement and the accompanying prospectus by reference. You should read this prospectus supplement and the accompanying prospectus together with additional information described below under the headings &#147;Where You Can Find
More Information&#148; and &#147;Incorporation of Certain Documents by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus supplement or the accompanying prospectus will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference in this prospectus supplement or the accompanying prospectus modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute
a part of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus supplement, the accompanying prospectus, the
documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with the offering. We have not, and the underwriters have not, authorized any other person to provide you with different information. If
anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The
distribution of this prospectus supplement and the offering of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about,
and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer
to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. You should assume that the
information appearing in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references in this prospectus supplement to &#147;Inovio,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148;
&#147;the company&#148; or similar words refer to Inovio Pharmaceuticals, Inc., together with our consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained or incorporated by reference in this prospectus supplement. Because it is only a summary, it does not contain
all of the information that may be important to you or that you should consider before making an investment in our securities. You should carefully read the entire prospectus and the accompanying prospectus, including the information contained under
the caption &#147;Risk Factors&#148; and elsewhere in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> the information under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of
this prospectus supplement and other information that we file from time to time with the SEC as well as the financial statements and related notes and the other information incorporated by reference herein, before making an investment decision. See
&#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; in this prospectus supplement. This prospectus supplement may add to, update or change information in the accompanying prospectus.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus, or HPV, as well as cancer and infectious diseases. Our platform harnesses the power of
in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use proprietary technology to design DNA plasmids which are small circular DNA molecules that work like software the body&#146;s cells can download to
produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA delivery devices help our DNA medicines enter the body&#146;s cells for optimal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead candidate is <FONT STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of recurrent respiratory papillomatosis, or RRP, a life-long, rare
disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by <FONT STYLE="white-space:nowrap">HPV-6</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-11</FONT> genotypes. Although mostly benign,
these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. The standard of care for RRP is surgery. The most widely cited U.S. epidemiology data, published in 1995, estimated that there were
14,000 active cases for both adults and juveniles, and about 1.8 new cases per 100,000 adults each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our completed Phase 1/2 clinical trial of <FONT
STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of <FONT STYLE="white-space:nowrap">HPV-6</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-11-associated</FONT></FONT> RRP, 81.3% of patients experienced a
reduction in the number of surgical interventions in the year following administration of <FONT STYLE="white-space:nowrap">INO-3107,</FONT> when compared with the year prior to treatment. In February 2023, we announced data from the second cohort of
our Phase 1/2 clinical trial, which followed the announcement of the first cohort in October 2022. In the second cohort of 11 patients who were administered <FONT STYLE="white-space:nowrap">INO-3107</FONT> via an exploratory side port injection
needle, 10 of the 11 patients (91%) saw a reduction in surgical interventions in the year following initial treatment, with the measurement beginning on Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was
a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior to treatment. <FONT STYLE="white-space:nowrap">INO-3107</FONT> was well-tolerated and immunogenic among
patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used
to support the submission of a Biologic License Application, or BLA, for review under the FDA&#146;s accelerated approval program. As part of submitting our BLA under the accelerated program, which we plan to do in the second half of 2024, we will
need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">INO-3112,</FONT> a DNA medicine candidate targeting HPV
16/18 combined with a DNA plasmid encoding for human <FONT STYLE="white-space:nowrap">IL-12</FONT> as an immune activator, for the treatment of oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat
cancer. The incidence of <FONT STYLE="white-space:nowrap">HPV-related</FONT> throat cancer has increased rapidly in recent years in the United States, with an estimated approximately 20,000 new cases each year.
<FONT STYLE="white-space:nowrap">HPV-related</FONT> throat cancer has surpassed cervical cancer as the most common <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancer. In the United States, men are four to five times more likely to be
diagnosed with <FONT STYLE="white-space:nowrap">HPV-associated</FONT> oropharyngeal cancers than women. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2024, we announced a clinical
collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of <FONT STYLE="white-space:nowrap">INO-3112</FONT> and LOQTORZI <FONT STYLE="white-space:nowrap">(toripalimab-tpzi)</FONT> in a clinical trial for
patients with locoregionally advanced, high-risk, HPV16/18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial, pending alignment with the FDA on study design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">INO-5401,</FONT> an immunotherapy consisting of three DNA plasmids encoding for three tumor-associated
antigens, for the treatment of glioblastoma multiforme, or GBM, an aggressive type of brain cancer that accounts for more than 50% of all primary malignant brain tumors. GBM is one of the most complex, deadly, and treatment-resistant cancers. In the
United States, nearly 15,000 people were expected to receive a GBM diagnosis in 2023, and it is estimated that more than 10,000 individuals will succumb to the disease each year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our development efforts with the product candidates described above, we are actively developing or planning to develop DNA medicines for other
indications, including <FONT STYLE="white-space:nowrap">HPV-related</FONT> anal dysplasia; cancers in people with certain gene mutations; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical
trials of a DNA medicine candidate for the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in August 2023 that we were ceasing development for this
indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current development status of our pipeline of DNA medicines is summarized in the chart below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g819343g00k05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The
Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Coherus </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biosciences, Defense Advanced Research Projects Agency, the U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute,
National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army
Institute of Research, and the Wistar Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our DNA medicine candidates are in the research and development phase. We have not generated any
revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize <FONT STYLE="white-space:nowrap">INO-3107</FONT> and our other product
candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including
extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful
in our research and development efforts, and we may never generate sufficient product revenue to be profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully
in the &#147;Risk Factors&#148; section of this prospectus supplement immediately following this prospectus supplement summary and in the &#147;Risk Factors&#148; section in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2023, which is incorporated by reference in this prospectus supplement. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable
future and may never become profitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and
proprietary device technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which
may prove difficult or costly to obtain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful
DNA medicine products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a
novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our
investigational medicines, or obtain regulatory approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine
candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary
devices and DNA medicine candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply
adequate resources to their relationships with us, our product development and potential for profitability will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have agreements with government agencies that are subject to termination and uncertain future funding.
Termination or cessation of funding would have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our operating results may be harmed if our corporate restructuring plans and cost reduction efforts do not
achieve the anticipated results or cause undesirable consequences. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our
business, financial condition and reputation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new,
disruptive technology may impede our ability to develop and commercialize our DNA medicines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have entered into collaborations with Chinese companies and rely on clinical materials manufactured in China
for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business,
financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies,
and we may not be able to ensure their protection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and
time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Failure or perceived failure to comply with laws, regulations, contracts, self-regulatory schemes, notices and
other obligations related to data privacy and security (including security incidents) could harm our business. Compliance or the actual or perceived failure to comply with such obligations could increase our costs and otherwise negatively affect our
operating results and business. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in June 2001. Our principal executive offices are located at 660 W. Germantown Pike, Suite 110,
Plymouth Meeting, Pennsylvania 19462. Our telephone number is (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;INO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internet website address is
<I>www.inovio.com</I>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus.
We have included our website address in this prospectus supplement solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO, CELLECTRA, the INOVIO logo, and our
other trademarks or service marks appearing in this prospectus are our property. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the &reg; and TM symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this prospectus supplement and the accompanying
prospectus are the property of their respective owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.&nbsp;Smaller</FONT>
reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive compensation. We will
remain a smaller reporting company until the last day of any fiscal year for so long as either (1)&nbsp;the market value of our shares of common stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;does</FONT> not equal or exceed
$250.0&nbsp;million as of the prior June 30th, or (2)&nbsp;our annual revenues did not equal or exceed $100.0&nbsp;million during such completed fiscal year and the market value of our shares of common stock held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;did</FONT> not equal or exceed $700.0&nbsp;million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations, it may make the comparison of our
financial statements with other public companies difficult or impossible. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us </B></P></TD>
<TD>2,536,258 shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Pre-funded warrants offered by us </B></P></TD>
<TD>We are also offering, in lieu of shares of common stock to investors who so choose, pre-funded warrants to purchase up to 2,135,477 shares of common stock. The purchase price of each pre-funded warrant will equal the price per share at which the
shares of common stock are being sold in this offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share. Each pre-funded warrant will be immediately exercisable for one share of common stock. Each pre-funded
warrant will be exercisable at any time after the date of issuance of such pre-funded warrant, subject to a beneficial ownership limitation described herein. This prospectus supplement also relates to the offering of the shares of common stock
issuable upon exercise of such pre-funded warrants. See &#147;Description of the Pre-Funded Warrants&#148; on page S-16 of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding immediately after this&nbsp;offering </B></P></TD>
<TD>25,329,333 shares (excluding any shares of common stock issuable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P></TD>
<TD>We currently intend to use the net proceeds from this offering primarily for the development of our clinical pipeline and for general corporate purposes. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-12.</FONT>
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors </B></P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of
certain factors you should carefully consider before deciding to invest in our securities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market symbol </B></P></TD>
<TD>&#147;INO&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There is no established trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to list the pre-funded warrants on the Nasdaq Capital Market, any other national securities
exchange or any other nationally recognized trading system. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion is based on 22,793,075 shares of our common stock
outstanding as of December&nbsp;31, 2023, but excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,128,864 shares issuable upon exercise of outstanding stock options pursuant to our equity incentive plans, at a
weighted average option exercise price of $58.76 per share as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">274,794 shares issuable upon vesting of service-based restricted stock units outstanding under our equity
incentive plans as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">275 shares issuable upon the conversion of outstanding Series C Cumulative Convertible Preferred Stock as of
December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,459,587 shares reserved for future issuance under our equity incentive plans as of December&nbsp;31, 2023.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding as of December&nbsp;31, 2023 presented herein, as well as the number of shares appearing in the four
bullet points above, which are excluded from the outstanding share total as of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2023, reflect a retroactive adjustment for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-12</FONT></FONT> reverse stock split effected on
January&nbsp;24, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise or conversion of outstanding stock options, restricted stock units or convertible preferred stock;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the pre-funded warrants being offered hereby. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities is subject to numerous risks as discussed more fully below and under the caption &#147;Risk Factors&#148; in the
accompanying prospectus and our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which we incorporate by reference herein, and other information that we file from time to time with the SEC after the date of this
prospectus supplement and which we incorporate by reference herein. Any of these risks could adversely affect our financial condition and results of operations or our ability to execute our business strategy. You should read and consider carefully
all the information set forth and incorporated by reference in this prospectus supplement and the accompanying prospectus before deciding whether to invest in our securities. The risks and uncertainties we have described are not the only ones facing
our company. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also affect our business operations. See &#147;Incorporation of Certain Documents by Reference.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional
capital, including as a result of this offering, may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs through a combination of equity offerings, debt
financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity securities, including from this offering, or convertible
debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a securityholder. Debt financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be
required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with
third parties when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock or pre-funded warrants in this offering, you will suffer immediate dilution of
your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price of our common stock to be sold in this offering is substantially higher than the net tangible book value per share of
our common stock. Therefore, if you purchase shares of our common stock or pre-funded warrants in this offering, you will pay a price per share or per pre-funded warrant that substantially exceeds our net tangible book value per share after this
offering. Based on the public offering price of $7.693&nbsp;per share and $7.692&nbsp;per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each such pre-funded warrant (and
excluding shares of common stock issued or any resulting accounting associated with the pre-funded warrants) you will experience immediate dilution of $1.74&nbsp;per share, representing the difference between our as adjusted net tangible book value
per share after giving effect to this offering and the public offering price. To the extent outstanding options are exercised or shares of our common stock are issued upon the settlement of outstanding restricted stock units, you will incur further
dilution. Furthermore, if the pre-funded warrants are exercised, you will incur further dilution. For additional information on the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the
proceeds in ways with which you do not agree and in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we currently intend to use the
net proceeds from this offering, together with our existing cash and cash equivalents, in the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus supplement, our management will have broad discretion in the
application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to
use our net proceeds from this offering. The failure by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our
product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales or other issuances of our common stock could depress the market for our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock, or the perception by the market that those sales could occur, could cause the market price of our
common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future. In connection with this offering, we, and our executive officers and directors have entered into
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements for a period of 90 days following this offering. These <FONT STYLE="white-space:nowrap">lock-up</FONT> obligations may be released prior to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period at the sole discretion of the representatives of the underwriters. See &#147;Underwriting&#148; in this prospectus supplement for additional information. Upon expiration or earlier release of these <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements, we and our executive officers and directors, and their applicable affiliates, may sell shares into the market, which could adversely affect the market price of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the pre-funded warrants being offered in this offering. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no public trading market for the pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not
intend to apply to list the pre-funded warrants on any securities exchange or nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of the pre-funded warrants will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not receive any additional funds upon the exercise of the pre-funded warrants. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each pre-funded warrant may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead
would receive upon such exercise the net number of shares of our common stock determined according to the formula set forth in the pre-funded warrant. Accordingly, we may not receive any additional funds upon the exercise of the pre-funded warrants.
If a pre-funded warrant is exercised for cash, we will not receive any meaningful additional funds upon the exercise of the pre-funded warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of any pre-funded warrants purchased in this offering will have no rights as holders of our common stock with respect to the shares of common
stock underlying such pre-funded warrants until such holders exercise their pre-funded warrants and acquire our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until holders of
pre-funded warrants acquire shares of our common stock upon exercise of the pre-funded warrants, holders of pre-funded warrants will have no rights with respect to the shares of our common stock underlying such pre-funded warrants including with
respect to dividends and voting rights. Upon exercise of the pre-funded warrants, the holders will be entitled to exercise the rights of a holder of our common stock with respect to the shares of common stock underlying such pre-funded warrants only
as to matters for which the record date occurs after the exercise date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial holders of our common stock may not be permitted to exercise
pre-funded warrants that they hold. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of a pre-funded warrant will not be entitled to exercise any portion of any pre-funded warrant
which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock outstanding
immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities then
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. Such percentage may be increased by the holder of the pre-funded warrant to any other
percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from the holder to us. As a result, you may not be able to exercise your pre-funded warrants for shares of our common stock at a time when it would be financially beneficial
for you to do so. In such circumstance you could seek to sell your pre-funded warrants to realize value, but you may be unable to do so in the absence of an established trading market for the pre-funded warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC that are incorporated by reference herein
contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and
such forward-looking statements involve risks and uncertainties. All statements, other than statements of historical fact, contained in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and
therein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expects,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative or plural of those terms, and similar expressions intended to identify statements about the
future, although not all forward-looking statements contain these words. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to be materially different from the information expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in
this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans with respect to our ongoing and planned clinical trials for our DNA medicine candidates, including the
timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop our current and future product candidates for any additional indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our DNA medicine candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential clinical benefits and attributes of our current product candidates and any future product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current and any future collaborations for the development and commercialization of our current and future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any current or future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility of our DNA medicine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenues, expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our beliefs about the length of time over which our capital resources will be sufficient to meet our anticipated
cash requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we are under no obligation to update any of the
forward-looking statements after the filing of this prospectus supplement or the accompanying prospectus to conform such statements to actual results or to changes in our expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such statements are based on currently available operating, financial and competitive information and are
subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our history of losses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lack of products that have received regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties inherent in clinical trials and product development programs, including but not limited to the fact
that <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical results may not be indicative of results achievable in other trials or for other indications, that the results from one study may not necessarily be reflected or supported by the
results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is
uncertain and failure can occur at any time during the clinical trial process, and that our proprietary device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manufacture our DNA medicine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations, licensing or other arrangements and to receive development,
regulatory and commercialization event-based payments under those agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability or potential availability of alternative therapies or treatments for the conditions we or our
collaborators target, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of
others or can withstand claims of invalidity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government healthcare legislation and proposals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of current or future litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should refer to the risks and uncertainties described in the &#147;Risk Factors&#148; section contained in this prospectus supplement, the accompanying
prospectus and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus, for a discussion of important factors that may
cause our actual results to differ materially from those expressed or implied by our forward-looking statements. We qualify all of the information presented or incorporated by reference in this prospectus supplement and the accompanying prospectus,
and particularly our forward-looking statements, by these cautionary statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus
supplement and the accompanying prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements and our management is responsible for the accuracy of such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $33.2&nbsp;million, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. We will receive nominal proceeds, if any, upon exercise of the pre-funded warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use
the net proceeds from this offering primarily for the development of our clinical pipeline and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of
proceeds from this offering represents our current intentions based on our present plans and business condition. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the proceeds to be
received upon the completion of this offering. We may also use a portion of the proceeds to license, acquire or invest in complementary businesses, technology, products or assets. However, we have no current commitments to do so. The amount and
timing of our actual expenditures will depend on numerous factors, such as the timing and progress of our commercialization activities, research and development efforts, the timing of regulatory review and approval of our product candidates, the
timing and progress of any partnering efforts, and the competitive environment for our product candidates. As a result, our management will have broad discretion over the use of the proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending application of the net proceeds as described above, we intend to invest the proceeds in short term, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the
operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock or pre-funded warrants in this offering, your interest will be diluted immediately to the extent of the difference between
the public offering price per share or pre-funded warrant you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of December&nbsp;31, 2023 was $117.3&nbsp;million, or $5.15 per share of common stock. Historical net tangible book
value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding on December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to our issuance and sale of 2,536,258&nbsp;shares of common stock and pre-funded warrants to purchase up to 2,135,477&nbsp;shares of our
common stock in this offering at a public offering price of $7.693&nbsp;per share and $7.692&nbsp;per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each such pre-funded
warrant (and excluding shares of common stock issued or any resulting accounting associated with the pre-funded warrants), and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us and excluding the
proceeds, if any, from the exercise of the pre-funded warrants issued pursuant to this offering or any resulting accounting associated with the pre-funded warrants, our as adjusted net tangible book value as of December&nbsp;31, 2023 would have been
$150.6&nbsp;million, or $5.95&nbsp;per share. This represents an immediate increase in net tangible book value per share of $0.80&nbsp;to existing stockholders and immediate dilution of $1.74&nbsp;in net tangible book value per share to new
investors purchasing securities in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors. The
following table illustrates this per share dilution to the new investors purchasing securities in this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;5.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to sale of shares of common stock and
pre-funded warrants in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculations above are based upon 22,793,075 shares of common stock outstanding as of December&nbsp;31, 2023 and exclude:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,128,864 shares issuable upon exercise of outstanding stock options pursuant to our equity incentive plans, at a
weighted average option exercise price of $58.76 per share as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">274,794 shares issuable upon vesting of service-based restricted stock units outstanding under our equity
incentive plans as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">275 shares issuable upon the conversion of outstanding Series C Cumulative Convertible Preferred Stock as of
December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,459,587 shares reserved for future issuance under our equity incentive plans as of December&nbsp;31, 2023.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding as of December&nbsp;31, 2023, as well as the number of shares appearing in the four bullet points
above, which are excluded from the outstanding share total as of December&nbsp;31, 2023, reflect a retroactive adjustment for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-12</FONT></FONT> reverse stock split effected
on January&nbsp;24, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the pre-funded warrants exercise the pre-funded warrants in full, the immediate dilution in as adjusted net
tangible book value per share to investors purchasing shares in this offering would be $2.21&nbsp;per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that options outstanding as of December&nbsp;31, 2023 have been or may be exercised or other
shares are issued, investors purchasing our securities in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have
sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom819343_8b"></A>DESCRIPTION OF THE PRE-FUNDED WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the pre-funded warrants being offered by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercisability</I>. The pre-funded warrants will be immediately exercisable, at the option of each holder, in whole or in part by delivering to us a duly
executed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. The holder may also exercise the pre-funded warrant through a &#147;cashless exercise,&#148; in
which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise Limitations</I>. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a pre-funded warrant to the
extent that immediately prior to or after giving effect to such exercise the&nbsp;holder would own more than 9.99% of our outstanding common stock immediately after exercise, which percentage may be changed at the holder&#146;s election to a higher
or lower percentage not in excess of 19.99% (if&nbsp;exceeding such percentage would result in a change of control under Nasdaq Listing Rule&nbsp;5635(b) or any successor rule) upon 61&nbsp;days&#146; notice to us subject to the terms of the
pre-funded warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise Price</I>. Each pre-funded warrant offered hereby has an initial exercise price per share equal to $0.001. The
pre-funded warrants may be exercised at any time until the pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to adjustment in the event of stock dividends and
distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Subject to
compliance with any applicable securities laws, the pre-funded warrants are separately tradeable immediately after issuance at the option of the holders and may be transferred at the option of the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Listing</I>. There is no established public trading market for the pre-funded warrants and we do not expect a market to develop. In addition, we do not
intend to apply for listing of the pre-funded warrants on any securities exchange or recognized trading system, including the Nasdaq Capital Market. Without an active market, the liquidity of the pre-funded warrants will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fundamental Transactions</I>. In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any
reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of
more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive
upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights as a Stockholder</I>. Except as otherwise provided in the pre-funded warrants or by virtue of a holder&#146;s ownership of shares of our common
stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including the right to receive dividend payments, vote or respond to tender offers, until they exercise their pre-funded warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Agent</I>. We will act as warrant agent for the pre-funded warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_8a"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and short-term investments, our indebtedness and our total capitalization as of December&nbsp;31,
2023: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, giving effect to the repayment in full of our convertible senior promissory notes at their
maturity date of March&nbsp;1, 2024 in an aggregate amount of $16.9&nbsp;million; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments described above and
(ii)&nbsp;the issuance and sale of our common stock and pre-funded warrants in lieu thereof as contemplated by this prospectus supplement and our application of the net proceeds in the manner described in &#147;Use of Proceeds,&#148; after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information set
forth in the table below assumes no exercise of the pre-funded warrants sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the information in this table together
with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our financial statements and the accompanying notes
incorporated by reference in this prospectus supplement and in the accompanying prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma<BR>As Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="padding-bottom:4pt ;"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145,293,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,345,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,576,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indebtedness:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible senior notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,770,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,770,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock, par value $0.001 per share, 1,091 shares authorized and issued and 9
shares outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 600,000,000 shares authorized, 22,793,075 shares issued and
outstanding, actual and pro forma, 25,329,333 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740,954,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740,954,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,774,182,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,622,965,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,623,142,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,623,142,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(662,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(662,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(662,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,349,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,171,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,402,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,119,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,171,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,402,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculations above are based upon 22,793,075 shares of common stock outstanding as of December&nbsp;31, 2023 and exclude:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,128,864 shares issuable upon exercise of outstanding stock options pursuant to our equity incentive plans, at a
weighted average option exercise price of $58.76 per share as of December&nbsp;31, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">274,794 shares issuable upon vesting of service-based restricted stock units outstanding under our equity
incentive plans as of December&nbsp;31, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">275 shares issuable upon the conversion of outstanding Series C Cumulative Convertible Preferred Stock as of
December&nbsp;31, 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,459,587 shares reserved for future issuance under our equity incentive plans as of December&nbsp;31, 2023.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding as of December&nbsp;31, 2023, as well as the number of shares appearing in the four bullet points
above, which are excluded from the outstanding share total as of December&nbsp;31, 2023, reflect a retroactive adjustment for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-12</FONT></FONT> reverse stock split effected
on January&nbsp;24, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_9"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF
OUR COMMON STOCK AND PRE-FUNDED WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal income tax consequences of the ownership and
disposition of our common stock and pre-funded warrants offered in this offering. This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not address the alternative minimum tax,
the special tax accounting rules under Section&nbsp;451(b) of the Internal Revenue Code of 1986, as amended, or the Code, the potential application of the Medicare contribution tax on net investment income, any estate or gift tax consequences or any
tax consequences arising under any laws other than U.S. federal income tax laws. The discussion below is based upon the provisions of the Code, applicable Treasury Regulations promulgated thereunder, published administrative pronouncements and
rulings of the Internal Revenue Service, or the IRS, and judicial decisions thereunder, all as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax
consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree
with such statements and conclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion assumes that the holder holds our common stock or pre-funded warrants as a &#147;capital
asset&#148; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address tax consequences relevant to certain holders that are subject to special treatment under the Code, such as
financial institutions, insurance companies, tax-exempt organizations, government organizations, broker-dealers and traders in securities, U.S. expatriates, &#147;controlled foreign corporations,&#148; &#147;passive foreign investment
companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, persons that hold our common stock or pre-funded warrants as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148;
&#147;synthetic security&#148; or integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons who hold common stock or pre-funded warrants that
constitute &#147;qualified small business stock&#148; under Section 1202 of the Code, or &#147;Section 1244 stock&#148; under Section 1244 of the Code, &#147;qualified foreign pension funds&#148; as defined in Section 897(l)(2) of the Code and
entities all of the interests of which are held by qualified foreign pension funds, partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. Such holders are urged to consult their
own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is
classified as a partnership for U.S. federal income tax purposes holds our common stock or pre-funded warrants, the U.S. federal income tax treatment of the partnership and the partners thereof generally depend on the status of the partner and the
activities of the partnership. Partnerships holding our common stock or pre-funded warrants and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding
and disposing of our common stock or pre-funded warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PERSONS
CONSIDERING THE PURCHASE OF OUR COMMON STOCK OR PRE-FUNDED WARRANTS PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME, ESTATE AND OTHER TAX CONSEQUENCES OF ACQUIRING, OWNING AND DISPOSING OF OUR
COMMON STOCK OR PRE-FUNDED WARRANTS IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR NON-U.S. TAX CONSEQUENCES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion, a &#147;U.S. Holder&#148; means a beneficial owner of common stock or pre-funded warrants that is for U.S. federal income
tax purposes any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S.
persons have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;Non-U.S. Holder&#148; is, for U.S. federal income tax purposes, a beneficial owner of common stock or pre-funded warrants that is neither a U.S.
Holder, nor a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Characterization of the
pre-funded warrants for tax purposes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the characterization of the pre-funded warrants for U.S. federal income tax purposes is not entirely
clear, because the exercise price of the pre-funded warrants is a nominal amount, we expect to treat the pre-funded warrants as stock for U.S. federal income tax purposes. Accordingly, no gain or loss should be recognized upon the exercise of a
pre-funded warrant and, upon exercise, the holding period of a pre-funded warrant should carry over to the share received. Similarly, the tax basis of the pre-funded warrant should carry over to the share received upon exercise, increased by the
exercise price. Except where specifically noted below, the following discussion assumes our pre-funded warrants are treated as our stock. Some portions of the below discussion make reference to potential consequences associated with the purchase,
ownership and disposition of the pre-funded warrants independent of their potential characterization as stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our position with respect to the
characterization of pre-funded warrants is not binding on the IRS and the IRS may treat the pre-funded warrants as warrants to acquire our stock and, if so, the amount and character of your gain with respect to an investment in our pre-funded
warrants could change. You should consult your tax advisor regarding the characterization of pre-funded warrants for U.S. federal income tax purposes, and the consequences to you of an investment in the pre-funded warrants based on your own
particular facts and circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences to U.S. Holders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never
declared or paid any cash dividends on our capital stock, and we do not anticipate declaring or paying, in the foreseeable future, any such cash dividends. However, if we make cash or other property distributions on our common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Dividends received by non-corporate holders
are generally taxed at long-term capital gains rates, provided certain holding period requirements are satisfied. Dividends received by a corporation may be eligible for a dividends received deduction, subject to applicable limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts that exceed such current and accumulated earnings and profits and, therefore, are not treated as dividends for U.S. federal income tax purposes will
constitute a return of capital and will first be applied against and reduce a holder&#146;s tax basis in our common stock, but not below zero. Any amount distributed in excess of basis will be treated as gain realized on the sale or other
disposition of our common stock and will be treated as described under the section titled &#147;Sale or Other Disposition of Our Common Stock or Pre-Funded Warrants&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Disposition of Common Stock or Pre-Funded Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, gain or loss realized on the sale or other disposition of our common stock or pre-funded warrants will generally be
capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder has held the common stock or pre-funded warrants for more than one year. The amount of the gain or loss will equal the difference between such U.S. Holder&#146;s tax
basis in the common stock or pre-funded warrants disposed of and the amount realized on the disposition. Long-term capital gains recognized by non-corporate U.S. Holders will be subject to reduced tax rates. The deductibility of capital losses is
subject to limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting requirements generally will apply to payments of dividends on our common stock, and gross proceeds on the sale or other disposition of
our common stock and pre-funded warrants, unless the U.S. Holder is an exempt recipient (such as a corporation). Backup withholding (currently at a 24% rate) will apply to those payments if the U.S. Holder fails to provide its correct taxpayer
identification number or certification of exempt status on an IRS Form W-9 (Request for Taxpayer Identification Number and Certification), or if the U.S. Holder is notified by the IRS that it has failed to report in full payments of interest and
dividend income. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. Holder&#146;s U.S. federal income tax liability provided the required
information is furnished timely to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If backup withholding is applied to you, you should consult with your own tax advisor to determine whether
you have overpaid your U.S. federal income tax, and whether you are able to obtain a tax refund or credit of the overpaid amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences
to Non-U.S. Holders </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above under &#147;Tax Consequences to U.S. Holders&#151;Distributions on Our Common Stock,&#148; we have never declared or paid any cash
dividends on our capital stock, and we do not anticipate declaring or paying, in the foreseeable future, any such cash dividends. However, distributions, if any, made on our common stock to a Non-U.S. Holder to the extent made out of our current or
accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. federal income tax purposes. To the extent distributions on our common stock, if any, exceed our current and
accumulated earnings and profits, they will first reduce the Non-U.S. Holder&#146;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount distributed, and taxed in the same manner
as gain realized from a sale or other disposition of common stock as described under &#147;Sale or Disposition of Common stock or Pre-Funded Warrants&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts, dividends paid to a Non-U.S. Holder
generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a
Non-U.S. Holder generally will be required to provide us or our paying agent with a properly executed IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the case of entities), or other appropriate form, certifying the Non-U.S.
Holder&#146;s entitlement to benefits under that treaty. This certification must be provided to us and/or our paying agent prior to the payment of dividends and must be updated periodically. In the case of a Non-U.S. Holder that is an entity,
Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of such tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If
a Non-U.S. Holder holds our common stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#146;s agent will then be required
to provide certification to us and/or our paying agent, either directly or through other intermediaries. If a Non-U.S. Holder is eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and such Non-U.S. Holder does not
timely file the required certification, such Non-U.S. Holder may be able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not required to withhold tax on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder&#146;s conduct of a trade
or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such Non-U.S. Holder maintains in the United States) if a properly executed IRS Form W-8ECI,
stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
general, such effectively connected dividends will be subject to U.S. federal income tax on a net-income basis at the regular rates applicable to U.S. residents. A corporate Non-U.S. Holder
receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax
treaty) on the corporate Non-U.S. Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for
different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Disposition of Common Stock or Pre-Funded Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to U.S. federal income tax
with respect to gain realized on a sale or other disposition of our common stock or pre-funded warrants unless (a) the gain is effectively connected with a trade or business of such Non-U.S. Holder in the United States (and, if required by an
applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States), (b) the Non-U.S. Holder is a nonresident alien individual and is present in the United States for 183 or more
days in the taxable year of the disposition and certain other requirements are met or (c) our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a &#147;United States real property holding
corporation&#148; within the meaning of Code Section 897(c)(2) at any time within the shorter of the five- year period preceding such disposition or such Non-U.S. Holder&#146;s holding period. In general, we would be a United States real property
holding corporation if our interests in U.S. real estate comprise (by fair market value) at least half of our business assets. We believe that we are not currently and do not anticipate becoming, a United States real property holding corporation,
although there can be no assurance we will not become a United States real property holding corporation in the future. Even if we are treated as a United States real property holding corporation, gain realized by a Non-U.S. Holder on a disposition
of our common stock will not be subject to U.S. federal income tax so long as (1) the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (i) the five-year period
preceding the disposition or (ii) the Non-U.S. Holder&#146;s holding period and (2) our common stock is &#147;regularly traded&#148; (as defined in applicable Treasury Regulations) on an established securities market. Similarly, gain realized by a
Non-U.S. Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1) the Non-U.S. Holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the
shorter of (i) the five-year period preceding the disposition or (ii) the Non-U.S. Holder&#146;s holding period and (2) our common stock is &#147;regularly traded&#148; (as defined in applicable Treasury Regulations) on an established securities
market. There can be no assurance that our common stock will qualify or continue to qualify as regularly traded on an established securities market, and our pre-funded warrants are not currently listed on an established securities market. If any
gain on a Non-U.S. Holder&#146;s disposition is taxable because we are a United States real property holding corporation and the Non-U.S. Holder&#146;s ownership of our common stock or pre-funded warrants exceeds 5%, or our common stock and
pre-funded warrants is not &#147;regularly traded&#148; on an established securities market, the Non-U.S. Holder will be taxed on such disposition generally in the same manner as gain that is effectively connected with the conduct of a U.S. trade or
business (subject to the provisions under an applicable income tax treaty), except that the branch profits tax generally will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Non-U.S.
Holder described in (a) above will be required to pay tax on the net gain derived from the sale at regular U.S. federal income tax rates, and corporate Non-U.S. Holders described in (a) above may be subject to the additional branch profits tax at a
30% rate or such lower rate as may be specified by an applicable income tax treaty. A Non-U.S. Holder described in (b) above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income
tax treaty, which gain may be offset by certain U.S.- source capital losses (even though the Non-U.S. Holder is not considered a resident of the United States), provided that the Non-U.S. Holder has timely filed U.S. federal income tax returns with
respect to such losses. Non-U.S. Holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, we must report information to the IRS with respect to any distributions we pay on our common stock (even if the payments are exempt from
withholding), including the amount of any such distributions, the name and address of the recipient and the amount, if any, of tax withheld. A similar report will be sent to the Non-U.S. Holder to whom any such distributions are paid. Pursuant to
tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid by us (or our paying agents) to a Non-U.S. Holder may also be subject to U.S. backup withholding (currently at a rate of 24%). U.S. backup
withholding generally will not apply to a Non-U.S. Holder who provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-ECI (as applicable), or otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding
may apply if the payer has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. information
reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock or pre-funded warrants effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and
backup withholding requirements may be avoided if the Non-U.S. Holder provides a properly executed IRS Form W-8BEN or IRS Form W-8BEN-E or otherwise meets documentary evidence requirements for establishing non-U.S. person status or otherwise
establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a
non-U.S. office of a non-U.S. broker. Information reporting and backup withholding requirements, however, may apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S.
person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations generally will be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability of persons
subject to backup withholding, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign accounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sections 1471 through 1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments to a foreign financial
institution (as specifically defined by applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information
regarding certain U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). FATCA also generally imposes a federal withholding
tax of 30% on certain payments to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding
substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign
financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding provisions described above
currently apply to payments of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would
eliminate the federal withholding tax of 30% that otherwise would apply to the gross proceeds of a disposition of our common stock or pre-funded warrants. In its preamble to such proposed regulations, the U.S. Treasury Department stated that
taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their
investment in our common stock or pre-funded warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF
PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK OR PRE-FUNDED WARRANTS, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into an underwriting agreement with Oppenheimer&nbsp;&amp; Co. Inc. and Citizens JMP Securities, LLC as representatives of the underwriters
named below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides for the purchase of a specific number of shares of common stock and pre-funded warrants by each of the
underwriters. The underwriters&#146; obligations are several, which means that each underwriter is required to purchase a specified number of shares and pre-funded warrants, but is not responsible for the commitment of any other underwriter to
purchase shares and pre-funded warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to
purchase the number of shares of common stock and pre-funded warrants set forth opposite its name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrants</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,445,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1,217,222</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citizens JMP Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">918,255</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,536,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">2,135,477</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters have agreed to purchase all of the shares and pre-funded warrants offered by this prospectus supplement
(other than those covered by the option to purchase additional described below) if any are purchased. Under the underwriting agreement, if an underwriter defaults in its commitment to purchase securities, the commitments of <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated, depending on the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares and pre-funded warrants are expected to be ready for delivery on or about April&nbsp;18, 2024, against payment in immediately available funds. The
underwriters are offering the securities subject to various conditions and may reject all or part of any order. The representatives have advised us that the underwriters propose to offer the shares and pre-funded warrants directly to the public at
the public offering prices that appear on the cover page of this prospectus supplement. In addition, the representatives may offer some of the shares to other securities dealers at such price less a concession of $0.276948 per share. After the
shares are released for sale to the public, the representatives may change the offering price and other selling terms at various times. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us, before expenses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per Pre-<BR>Funded<BR>Warrant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.69300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$7.69200</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,937,521.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.46158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$0.46152</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156,251.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.23142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">$7.23048</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,781,270.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our total expenses of the offering, excluding the underwriting discounts and commissions, will be
approximately $550,000, which includes the fees and expenses for which we have agreed to reimburse the underwriters, including fees and expenses of their counsel, up to a maximum amount of $100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our officers and directors have agreed to a 90 day &#147;lock up&#148; with respect to shares of common stock and other of our securities that they
beneficially own, including securities that are convertible into shares of common stock and securities that are exchangeable or exercisable for shares of common stock. This means that, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to certain exceptions, for a period of 90 days following the date of this prospectus supplement, we and such persons may not offer, sell, pledge or otherwise dispose of these securities
without the prior written consent of Oppenheimer&nbsp;&amp; Co. Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rules of the SEC may limit the ability of the underwriters to bid for or purchase
shares before the distribution of the shares is completed. However, the underwriters may engage in the following activities in accordance with the rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions &#150; The representatives may make bids or purchases for the purpose of pegging, fixing
or maintaining the price of the shares, so long as stabilizing bids do not exceed a specified maximum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over-allotments and syndicate covering transactions &#150; The underwriters may sell more shares of our common
stock in connection with this offering than the number of shares than they have committed to purchase. This over-allotment creates a short position for the underwriters. This short sales position may involve either &#147;covered&#148; short sales or
&#147;naked&#148; short sales. Covered short sales are short sales made in an amount not greater than the underwriters&#146; over-allotment option to purchase additional shares in this offering described above. Because we have not granted the
underwriter an option to purchase additional shares, the underwriter must close out any short position by purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Penalty bids &#150; If the representatives purchase shares in the open market in a stabilizing transaction or
syndicate covering transaction, they may reclaim a selling concession from the underwriters and selling group members who sold those shares as part of this offering. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Passive market making &#150; Market makers in the shares who are underwriters or prospective underwriters may
make bids for or purchases of shares, subject to limitations, until the time, if ever, at which a stabilizing bid is made. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to
other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales or to stabilize the market price of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or
mitigating a decline in the market price of our common stock. As a result, the price of the shares of our common stock may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an
effect on the price of the shares if it discourages resales of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters makes any representation or prediction as to
the effect that the transactions described above may have on the price of the shares. These transactions may occur on the Nasdaq Capital Market or otherwise. If such transactions are commenced, they may be discontinued without notice at any time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Electronic Delivery of Preliminary Prospectus Supplement: </I>A prospectus supplement in electronic format may be delivered to potential investors by
one or more of the underwriters participating in this offering. The prospectus supplement in electronic format will be identical to the paper version of such prospectus supplement. Other than the prospectus supplement in electronic format, the
information on any underwriter&#146;s website and any information contained in any other website maintained by an underwriter is not part of the prospectus supplement or the registration statement of which this prospectus supplement and the
accompanying prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various
activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and
their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such
securities and instruments. Such investment and securities activities may involve securities and instruments of ours or our affiliates. The underwriters and their respective affiliates may also make investment recommendations and/or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>European Economic Area </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State
of the European Economic Area, each, a &#147;Relevant State&#148;, no securities have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the
securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus
Regulation), except that securities may be offered to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require the issuer or the representative to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any
securities or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with us and the representative that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of any securities being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial
intermediary will be deemed to have represented, acknowledged and agreed that the securities acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been
acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the
representative has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the representative and each of our and the representative&#146;s respective
affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision,
the expression an &#147;offer to the public&#148; in relation to the securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to
enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to the other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters are not acting for anyone other than the issuer and will not be responsible to anyone other than the issuer
for providing the protections afforded to their clients nor for providing advice in relation to the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United Kingdom </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to the United Kingdom, or the UK, no securities have been offered or will be offered pursuant to this offering to the public in the UK prior to
the publication of a prospectus in relation to the securities which is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provisions in Article 74 (transitional provisions) of the
Prospectus Amendment etc (EU Exit) Regulations 2019/1234, except that the securities may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, or
the FSMA, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require us or the representative to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the
expression an &#147;offer to the public&#148; in relation to the securities in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to
enable an investor to decide to purchase or subscribe for any securities, and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Canada </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be sold only to
purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act
(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance
with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are
exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s
province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI 33 105), the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of
interest in connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Israel </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the State of Israel, this prospectus supplement shall not be regarded as an offer to the public to purchase securities under the Israeli Securities Law,
5728 &#150; 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728 &#150; 1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First
Addendum of the Israeli Securities Law, 5728 &#150; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1968, subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase
securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#150; 1968. We have not and will not
distribute this prospectus supplement or make, distribute or direct an offer to subscribe for our securities to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728
&#150; 1968. In particular, we may request, as a condition to be offered securities, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of
the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#150; 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#150; 1968 regarding Qualified Investors is applicable to it;
(iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 &#150; 1968 and the regulations promulgated thereunder in connection with the offer to be issued securities; (iv)&nbsp;that the securities that it will be
issued are, subject to exemptions available under the Israeli Securities Law, 5728 &#150; 1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in
accordance with the provisions of the Israeli Securities Law, 5728 &#150; 1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their
identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by
the underwriters and their respective affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the securities, other than the underwriters, is authorized to make any further
offer of securities on our behalf or on behalf of the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Switzerland </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX or on any other stock exchange or
regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed with or approved
by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority, or the FINMA, and the offer of securities has not been
and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hong Kong </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been
offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell securities or debentures, whether as principal or agent; or to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong, or SFO, and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in
the Companies Ordinance (Cap. 32) of Hong Kong, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the CO, or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued
or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong
(except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and
any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this
prospectus supplement may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by
the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus supplement and the relevant offering documents and that he is not acquiring, and has not been offered any
securities in circumstances that contravene any such restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain legal matters will be passed upon for us by Cooley LLP, Reston, Virginia. The underwriters are being represented in connection with this offering by
Paul Hastings LLP, New York, New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial
statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to the securities offered hereby. This
prospectus supplement, which constitutes part of the registration statement, does not contain all the information set forth in the registration statement and its exhibits. For further information with respect to us and the securities offered by this
prospectus supplement, we refer you to the registration statement and its exhibits. Statements contained in this prospectus supplement as to the contents of any contract or any other document referred to are not necessarily complete, and in each
instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently subject to the information requirements of the Exchange Act, and in accordance therewith file periodic reports, proxy statements and other
information with the SEC. Some of this information may be accessed through the SEC&#146;s Internet address at <I>http://www.sec.gov</I>. We maintain a website at <I>http://www.inovio.com</I>. You may access our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed pursuant to Sections 13(a) or
15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. Except for the information incorporated by reference as noted herein,
our website and the information contained on that site, or connected to that site, are not incorporated into and are not a part of this prospectus supplement. We have included our website address in this prospectus supplement solely as an inactive
textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom821461_14"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information in documents we file with it, which means that we
can disclose important information to you by referring you to those documents. The information we incorporate by reference is considered to be a part of this prospectus supplement and accompanying prospectus, and information that we file later with
the SEC will automatically update and supersede this information. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus
supplement and the accompanying prospectus to the extent that a statement contained in or omitted from this prospectus supplement or the accompanying prospectus, or in any other subsequently filed document that also is or is deemed to be
incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. We incorporate by
reference the documents or information listed below and any future filings we make with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-14888)</FONT> under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (in each case, other than
those documents or the portions of those documents not deemed to be filed) until the offering is completed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;6, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000119312524007674/d722280d8k.htm">January&nbsp;12,
 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm">January&nbsp;25, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our definitive proxy statement on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572624000014/ino-2024xproxy.htm">April&nbsp;11,
 2024</A> (other than information furnished rather than filed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312514340354/d787144d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on September&nbsp;
12, 2014, including any amendments thereto or reports filed for the purposes of updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Exhibit 4.3</A> to our Annual
Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Form <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2023, filed
with the SEC on March&nbsp;6, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or
portion of any of the foregoing) or any other information that we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of our reports on annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports may also be obtained, free of charge, electronically through our investor relations website located at
<I>http://www.inovio.com</I> as soon as reasonably practical after we file such material with, or furnish it to, the SEC. The reference to our website does not constitute incorporation by reference of the information contained in our website. We do
not consider information contained on, or that can be accessed through, our website to be part of this prospectus or the related registration statement. We have included our website address in this prospectus supplement solely as an inactive textual
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request, and we will provide to you, a copy of these filings at no cost by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Inovio Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">660
W. Germantown Pike, Suite 110 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Plymouth Meeting, Pennsylvania 19462 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone:
(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g819343g94r84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell up to $300,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise
of any securities registered hereunder, including any applicable anti-dilution provisions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description
of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in
connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus
supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; under the federal securities laws and, as such, are subject to reduced public company reporting
requirements. See &#147;Summary&#151;Implications of Being a Smaller Reporting Company.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will sell these securities directly to
investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of
Distribution&#148; in this prospectus and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or
underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set
forth in a prospectus supplement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol &#147;INO.&#148; On
November&nbsp;8, 2023, the last reported sale price of our common stock was $0.38&nbsp;per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital Market or any securities
market or other exchange of the securities, if any, covered by the prospectus supplement. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing
in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#tx821461_3">Risk Factors</A>&#148; on page 7 of this prospectus and in any applicable prospectus
supplement and related free writing prospectus we have authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus.</I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is January 31, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx821461_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_1"></A>ABOUT THIS PROSPECTUS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate
offering price of $300,000,000. This prospectus provides you with a general description of the securities we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell
securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain
material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any
documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as
described under the heading &#147;Incorporation of Certain Information by Reference,&#148; before investing in any of the securities offered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS
PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any
agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing
prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to
buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to
buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any
information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is
delivered, or securities are sold, on a later date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contain
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the heading &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in this prospectus to &#147;Inovio,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Inovio Pharmaceuticals, Inc., together with our consolidated subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to a number of trademarks used in this prospectus which are important to our business, including SynCon<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, CELLECTRA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and the Inovio logo. Solely for convenience, the trademarks and trade names in this prospectus are referred to without
the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;and <SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert,
to the fullest extent under applicable law, their rights thereto. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#146; trademarks, trade dress, or
products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#147;Risk
Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the
information incorporated by reference into this prospectus, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is a part, before making your investment decision.</I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology
company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our pipeline of product candidates and deliver on the promise
of DNA medicines technology in treating and preventing a wide array of diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In clinical trials, our DNA medicine candidates have
shown the ability to generate immune responses, especially CD4+, CD8+, and memory <FONT STYLE="white-space:nowrap">T-cell</FONT> responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into
cells using our investigational proprietary smart device, CELLECTRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-3107</FONT> is our candidate
for the treatment of the <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease recurrent respiratory papillomatosis, or RRP. In October 2022 and February 2023, we announced data from the first and second cohorts of our Phase 1/2 clinical trial
of <FONT STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of <FONT STYLE="white-space:nowrap">HPV-6</FONT> and <FONT STYLE="white-space:nowrap">HPV-11</FONT> associated RRP. In this trial, treatment with
<FONT STYLE="white-space:nowrap">INO-3107</FONT> resulted in a statistically significant reduction of the median number of surgical interventions required to manage the disease during the first year following initial treatment, a result that
reinforces our belief that DNA medicines may play a key role in the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2023, we announced that we had received feedback from the U.S. Food and Drug Administration, or the FDA, that data from
our completed Phase 1/2 clinical trial of <FONT STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of RRP can be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#146;s accelerated approval
program. The FDA also advised that we will no longer be required to conduct our previously planned Phase 3 randomized, placebo-controlled trial; however, we will need to initiate a confirmatory clinical trial prior to BLA submission for accelerated
approval and will also need to satisfy all other FDA filing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our development efforts with <FONT
STYLE="white-space:nowrap">INO-3107,</FONT> we are also actively developing or planning to develop DNA medicines for <FONT STYLE="white-space:nowrap">HPV-related</FONT> precancers, including vulvar and anal dysplasia;
<FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers, including head&nbsp;&amp; neck cancer; and glioblastoma multiforme, or GBM, the most common aggressive type of brain cancer, as well as a potential vaccine booster to protect against the
Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of cervical high-grade squamous intraepithelial lesions but announced in August 2023 that we were ceasing development for this indication in the
United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to ApolloBio, our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, AstraZeneca, The Bill&nbsp;&amp;
Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, Indiana University, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute,
National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army
Institute of Research, and The Wistar Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our DNA medicine candidates are in the research and development phase. We have
not generated any revenues from the sale of any products, and we do not expect to generate any material revenues from commercial sales for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative
research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to
clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product
revenue to be profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in June 2001. Our principal executive offices are located at 660 W. Germantown
Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462. Our telephone number is (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;INO.&#148; Our internet website
address is <I>www.inovio.com</I>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this
prospectus or in deciding whether to purchase our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company,&#148; meaning that the market value of our shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either
(i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and
the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on
exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such
securities, either individually or in combination, up to a total aggregate offering price of $300,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free
writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of
securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material U.S. federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the
time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of securities unless it is accompanied by a prospectus supplement.</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in
the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B>. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to
a vote of stockholders and do not have any cumulative voting rights. Any election at a meeting of stockholders is determined by a plurality of the votes cast by the stockholders entitled to vote at the election, and all other matters are generally
determined by a majority of the votes cast on the matter. Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of funds legally available. In the event we liquidate,
dissolve or wind up, after payment of all of our debts and liabilities, and subject to the preferential rights, if any, of any outstanding preferred stock, the holders of our common stock are entitled to share ratably in all assets. Our common stock
has no preemptive or conversion rights or other subscription rights, and there are no redemptive or sinking funds provisions applicable to our common stock. We have received full payment for all outstanding shares of our common stock and cannot
require our stockholders to make further payments on the stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B>. We may issue shares of our preferred stock
from time to time, in one or more series. Under our certificate of incorporation, our board of directors has the authority, without further action by the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders (unless such stockholder action is required by applicable law or the rules of any stock exchange or market on which our securities are then traded), to designate up to 10,000,000
shares of preferred stock in one or more series and to determine the designations, voting powers, preferences and rights of each series of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend
rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series, any or all of which may be greater than
the rights of the common stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Any convertible preferred stock we may issue will be convertible into our common
stock or exchangeable for our other securities. Conversion may be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such
series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or
will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred
stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation
that contains the terms of the applicable series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B>. We may issue debt securities from
time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities
will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our
common stock or other securities. Conversion may be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any debt securities issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us
and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing
prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been filed as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B><I>.</I> We may
issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be
attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize
to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant
certificates containing the terms of the warrants that may be offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed
as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC before the issuance of such warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrants issued under this prospectus will be evidenced by warrant certificates.
Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of
warrants being offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_3"></A>RISK FACTORS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated
by all subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this
prospectus is a part. Each of the risk factors described in the documents referenced above could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and
the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements. These are based on our
management&#146;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in
the sections entitled &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained in the documents incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and are forward-looking statements. Within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, these forward-looking statements include statements regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize our DNA medicine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans with respect to our ongoing and planned clinical trials for our DNA medicine candidates, including the
timing of initiation, dosing of patients, enrollment and completion of these trials and of the anticipated results from these trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop our current and future product candidates for any additional indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our DNA medicine candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential clinical benefits and attributes of our current product candidates and any future product
candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research and develop any current and future product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current and any future collaborations for the development and commercialization of our current and future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any current or future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility of our DNA medicine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government healthcare legislation and proposals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional product candidates with significant commercial potential that are consistent
with our commercial objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding future revenues, expenses and needs for additional financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our beliefs about our capital expenditure requirements and the length of time over which our capital resources
will be sufficient to meet our anticipated cash requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from any offering under this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by the words &#147;may,&#148; &#147;might,&#148; &#147;can,&#148; &#147;will,&#148;
&#147;to be,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;objective,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;potential,&#148; &#147;likely,&#148; &#147;continue&#148; and &#147;ongoing,&#148; or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all
forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;Risk Factors&#148; section contained in the applicable
prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to
differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this
prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_5"></A>USE OF PROCEEDS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any
applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for
working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans,
commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any
securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_6"></A>DESCRIPTION OF CAPITAL STOCK</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description summarizes selected information regarding our capital stock, as well as relevant provisions of: (i)&nbsp;our
certificate of incorporation; (ii)&nbsp;our amended and restated bylaws; and (iii)&nbsp;the General Corporation Law of the State of Delaware, or the DGCL. The following summary is qualified in its entirety by, and should be read in conjunction with,
the certificate of incorporation and the amended and restated bylaws, copies of which have been filed as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and the applicable provisions of the DGCL. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation
authorizes us to issue up to 600,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share. Our board of directors may establish the rights and preferences of the preferred stock
from time to time. As of September&nbsp;30, 2023, 1,091 shares of preferred stock were designated Series C Cumulative Convertible Preferred Stock, of which 9&nbsp;shares were outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common
stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have any cumulative voting rights. Any election at a meeting of stockholders is determined by a plurality of the votes cast by
the stockholders entitled to vote at the election, and all other matters are generally determined by a majority of the votes cast on the matter. Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared
by our board of directors out of funds legally available. In the event we liquidate, dissolve or wind up, after payment of all of our debts and liabilities, and subject to the preferential rights, if any, of any outstanding preferred stock, the
holders of our common stock are entitled to share ratably in all assets. Our common stock has no preemptive or conversion rights or other subscription rights, and there are no redemptive or sinking funds provisions applicable to our common stock.
The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our
certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to
10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or
special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the
common stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely
affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally,
the issuance of preferred stock may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will fix the designations, voting powers, preferences and rights of each series, as well as the qualifications,
limitations or restrictions thereof, of the preferred stock of each series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitakeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested
stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as an entity or person who, together with the entity or person&#146;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of
interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that our board of directors may issue shares of undesignated preferred stock and
determine the rights, preferences and privileges of these shares, without stockholder approval and that all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent. Our certificate of incorporation
also does not provide for cumulative voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorization of undesignated preferred stock makes it possible for our board of
directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. These provisions are intended to discourage coercive takeover practices and inadequate takeover bids.
These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers
for our shares and may have the effect of delaying changes in our control or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the
benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover
proposals, because negotiation of takeover proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare. The transfer agent&#146;s address is 3rd Floor &#151; 510 Burrard St.,
Vancouver, BC V6C 3B9, and its telephone number is (604) <FONT STYLE="white-space:nowrap">661-0258.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Capital
Market</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;INO.&#148; The applicable prospectus supplement
will contain information, where applicable, as to any other listing, if any, on the Nasdaq Capital Market or any securities market or other exchange of the preferred stock covered by such prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_7"></A>DESCRIPTION OF DEBT SECURITIES</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in
part for other individual securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set
forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the
last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each
issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt
Securities&#8201;-&#8201;Consolidation, Merger or Sale&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities&#8201;-&#8201;General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add
to the rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and
Transfer</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide
otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities
that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series
are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee
is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are
registered at the close of business on the regular record date for the interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on
the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder
or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each
series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a
particular series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on
any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the
debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_8"></A>DESCRIPTION OF WARRANTS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related
free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or
more series. Warrants may be offered independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized
below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free
writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a
security that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant
agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this
prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are
offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to
the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free
writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including, to the extent
applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise
in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the
State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_9"></A>LEGAL OWNERSHIP OF SECURITIES</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to
the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have
made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors
in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered
in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
legal holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of
the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the holders, and
not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Indirect Holders</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global
security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#147;- Special Situations
When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be
permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution
that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed by the account rules of the investor&#146;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_10"></A>PLAN OF DISTRIBUTION</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule
415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of the Nasdaq Capital Market or any other securities exchange
or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale. Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the
terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement, other than securities covered by any overallotment or other option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change
from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide
agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making
at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in
overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to
be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or
agents who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act, during the
business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In
general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued
at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_11"></A>LEGAL MATTERS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP, Reston, Virginia. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in
the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_12"></A>EXPERTS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_13"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different
information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this
prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file
annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at <I>www.sec.gov</I> that contains reports, proxy and information statements, and other information regarding issuers, such as
us, that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of certain information filed by us with the SEC are also available on our website at
<I>http://www.inovio.com</I>. Information contained in or accessible through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus. We have included our website address as an inactive
textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx821461_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-14888.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are
incorporated by reference into this document: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000105572623000010/ino-20221231.htm">
<FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;1, 2023;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2023, June&nbsp;30, 2023 and September&nbsp;30, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000105572623000030/ino-20230331.htm">May<U></U>&nbsp;10,
2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000105572623000051/ino-20230630.htm">August<U></U>&nbsp;
9, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000105572623000055/ino-20230930.htm">November&nbsp;9, 2023</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572623000022/ino-2023xproxy.htm">Schedule
 14A</A>, filed with the SEC on March&nbsp;28, 2023, to the extent the information contained therein is filed and not furnished; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000119312523019738/d295438d8k.htm">January
<U></U>&nbsp;31, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000119312523148122/d458280d8k.htm">May<U></U>&nbsp;
18, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000119312523199683/d519359d8k.htm">August<U></U>&nbsp;
1, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001055726/000119312523253450/d567242d8k.htm">October<U></U>&nbsp;
10, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1055726/000119312523269347/d580286d8k.htm">November 2, 2023</A>, to the extent the information in such reports is filed and not furnished;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in our registration statement on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312514340354/d787144d8a12b.htm">Form<U></U><FONT STYLE="white-space:nowrap">&nbsp;8-A</FONT></A>, filed with the SEC on September&nbsp;12, 2014, including any amendments thereto or reports
filed for the purposes of updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Exhibit 4.3</A>&nbsp;to our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;1, 2023.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement and (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as
proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon
written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You
should direct any requests for documents to Inovio Pharmaceuticals, Inc., Attn: Investor Relations, 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462; telephone: (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this
prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus,
modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g819343g94r84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>2,536,258 shares of common stock </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Pre-funded warrants to purchase up to 2,135,477 shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>common stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Bookrunning Managers </I></B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"><B>Oppenheimer&nbsp;&amp; Co.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Citizens JMP</B></TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;15, 2024 </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g819343g00k05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g819343g00k05.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1FL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &9"^940X0DE-!"4      !                      .$))300Z
M  $K    $     $       MP<FEN=$]U='!U=     <     0VQR4V5N=6T
M    0VQR4P    !21T)#     $YM("!415A4    " !# $D 10 @ %( 1P!"
M        26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!_0
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  ( E,S,  $
M CA"24T$)@      #@             _@   .$))300-       $    'CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      8\   +%0    8 9P P #  :P P #4    !
M      $             "Q4   8\                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     LX0DE-! P     #R(    !    H
M %H   '@  "HP   #P8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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MRO<TZSO(NH>[?^9])4+<3);=8"P A[OSF?O'^6B5LM8W:VMP!P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<:8A4JBE0(UBU1#*]BE33I\<N5'<:0X\ZVRV"IUU:6VT[0&TMQ02D J( E1
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M+2*)3Y]Q3[E4T63;LZV9M/N))5%%%J])7+;OV=7=:MDM["VT(<6%OLH2E+A
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M7%K6XE+8 ]HAPI,*2J/;03)JJ8!P[>UU;@96E*%*5UI(&PA"4E2R;W1M)!!
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MCG 8.7!X#9']3.,$@C,6<ZKGM'=]<; VM(4;Q?N!D$^0O>;<!P<DX!))<%V
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M#O%HP<X)[ AF_P Y\9<L<MW!'/3$3%P(,B1NM!'@8D'?>]I*[N0.>^,'CZC
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MZ'VL,&"0)\,6T^4&("$T4/Y>O1_[1HV,]]'F8Y9E;SZ&JS,:+I"UFM11M+4
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M'KUL&_3BVX#_ !76"!,?;.HWP3E8T-N2!;/I3";?8A,_Z23KK;]1)OK-C;?
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MWU#6X&-N/NV#V [<-@,#D-^DIM9 ^Q%)G_2(/PH[WG2?,QBY_":+?L8Q;_&
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M]!:]MVXXY(?M!=/XACPXIF./[^Y;<YXM#L>/5W&'/6P:].+#NG1AP0-3FZ#
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MTFH!_P#R!YFT]HQ6?24V#'V0OB?U](@?ZH)OH!<QQQNI7B?L*9##%%HFCA!
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M2L)60R^IB=6MX>*_5Z=1ZA*N*A28:NEH1,F;+J6])4[KEV+/MBG3(H$D4N;
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M&&919D$R"GKM)M.U$$<Z&9,FFVI$"F.= NJT-0T;F09.M+B%T25)<4ZM<NU
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M<>WF]_AY:G"+  N-H#!\@-ZY+ODB)\.< Y+GRT^?)Q.,R(HL[6);D;2S@1<
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M$23PUW<G@,40AACU1N688>Q\T5<B(!X =AQCCK&5E?38*!/2:CFW^*J6"?\
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MZ5D$ST@SXF/\BZ+"QX?LF2>R)C3MW,CQ7?9SQP@P>"^\(1C!U JQ;OC^-IR
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M(=X 9<??97CN?^4CEXBW#D9XQU<'I ]%"3">@.8IF-*T@<9MF%H!GXQC2O\
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M6@+6E*IU3)C0G2.>S++W\KKJG+ZA;+KU(Z6G':=:W&%* !EM:T-J6D@@@E*
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M^Z!:+Y?0F?SC8$D'U>J'9/4J'= (O>Q';(^Y7)B8D@ .1G )([GD9\H?)#
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MXE9AF389E,ID8ACA,K?3*:3"2@1^QO#)<JE!&6T*BVRJG213,@I95MI4A)"
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M[1$]^-Q2QLB8-A<]QB0+[S$7V1H0,0[[4Y(KD4WPK39\B=+EC32K)-T<N.&
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M"S?0@$L0V<$EW6Y\,//W>^W"=(B3I;!WA< $-@0N#V+1.Y<PMR^7<#ESSQQ
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M.7#X4@Q=3Z)>@"! R-8' YKG)UCCF$W  UTL+8WB7PA^%5)!# ETSJ<$$,1
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MZ4[O[:OC:?XRR1KQM(X RRG:D?9@Q;0F\/FNTO+P^TN-00#^_5Z/ASV/."7
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MY+O[[*.>P'AMU^=X?FNM4#@N'_MQOV8@L>0Q+L'2/T#G_P 3NE6_^V.;M_\
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MSN'M8'^I)]MDLX8'@A\\?4>-%WQ/?V]PTD>?F>WM]W*)>2[ &; 3^( @F>"
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M (QNF<,SK? _F2T$9;VD#A@!WFL'8. >,Y#],.=W/RP_;6_$0?=%I;N)LML
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M(#'.,@,07#@SAS]VL]^!H?J-N!PPV[2.Q#^K9<,-S =1Y=E]<,&&.06V@^G
M]8GBR"P)?<020P>??SX8<]@O$SX^.Z<(.Q<.&),+CDPN3DL?)_1P3$'X<,.>
M/-]>&,B78.XX+F%QQYB8GR!]2[')8CIA'/A/X<1?#SDPM$#ER1GS9$(RW.6,
M);+@."Y.'X<[^.[ON1CCSB)F#1!\%\Y 'RL"&P0[C@C;TP^L\+\C&43L"X8[
M2 XVM$[EN<,2S%X@_E>)V&/,'C9CC@\'/BLF01QP1#P[:T#= ^YH]/:^"/*
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MO#$S=R"Q.,X8 ,!$Q$?46YYTU]^%]WSYTU/TC ' !Y# @D@Q&$]V,.(<.X(
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MBM*^-U56#ZR7."00GDG@L P:)]P!?AX2>F'RT[#/W[HOC3DPB%V( <,.''&
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M@P8)WD"\'=I%T@2<2U%@@DESW<MDYQSES"6(9HFB+EL<DG7?XF1N-P2=]]Y
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MQ%S$27)) ))]"#UNA8VM$#<!J.[2 ;;IU(..57O-B3))O).\$E4JDS!U)MI
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M7 >.+T PX#9)R/R)+]NO.G[&9BVX7[;VM;4FUQ>8QE9B97<?U1  OVR1:+Z
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M^,DX[<K[-SPFROD&IY9AYKH21-C!_N/^;-D$&%@VWK%7^3KZ.G)VF\[D\,T
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MT!+NP.!%_2?IA@ <Y)Q$.< F$LXY$63C! )]/,([>8X<?+#&3^9R >7B)?(
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M]O+;(?CRXQG!+$ N>>?AASSSWXM7IABLZ^!\85Y&3)!?LZ>2YP7. P;)W-P
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MZG#"8Y=P['(^7;"0\.YW!&W@Q,1SDCISS&&,W+Q'@Q XY#;F ,)P0',+OMA
M+G#=,/#W\_ 3V:XQB$(,4(8#^B7P0^&R_9PQ;:?RZ8<\\BWF3U9AAN26 (&6
M9HX0>"[@;@2#TQ,6OY$=\_2/IAAFR[DY[%CAQN81' A!EYVOZ8=O-O?B(GGX
M]GN]V$7 ()W#<W 'E(+P[8<;@S$,<-S$1%TP^6O/#Z'M&#)89SS"'(.0[A\!
M@-V"7AS@]/QY^?OPYY]V @$_AP.X(VE\DD@ 1./F ;Y_DY+GGGW8<ZQI?GR@
MSAPM$#G!(:(L2(B7SM81-V).#$Q,0.&',<^_@- 3;"R?E,63EG=LM&<@B$<
MAC@.^=S _A/D/IAL"/E>$D8AS\H'S/W#ON8 N7#@LPG7[[3P\+&^F&P,(P<,
M0P <0O" 8G#DPMQ$0,OANHOSWZ^ O$81SSSYG"!!W$L2Y):'!9RY$1P.Y<AF
M  R>IPW_  / \\Z2G,4/)?))AY8PG:0-Q:$ C@'( Q$1TPY[L .W?$?-"QB#
M%R0<#&YB[@,'A;YF< /?VG?Y;_=ASV6\/+0XS() $3")W&07[L=N2(7)<@C
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MGL[EFP[>AZ<_?]?=VHY_"\[AAXVEP.P!>%_0=L!L<',6=SEF'?SKWW^FF&X
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M.XD 9B/ !=W+PG8Q89PSGGGRPMNYX^^>WCC*)P3P26S"=Q!!Q$Y+N280Q?\
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M43N-AB\Q+G:&<.PQT FMX$,M6F+C^1_"& 9Y6 &?EF!+#)Z8B_ Z3N^OW=N
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M5_&3I-H)_5KB)$C]AQ,]]_+$A2:4_8M!A*\3GBEB+P@&.UX/Q%^?T"MP&)Y
M(8NQ%"LR]*UIR#H]8;JB9B-?VT8D]UQ&XR3EOHA,QTBZ36D2:6(VB20"<C @
M09 TM;3$@3Z6?8U@#V?B5\3Y#L#';('&-H?0D-VPS@-P#U;.8>E0V.0]'=";
M/Q(-YG[9(C36Y(._%7V;Z(HOTCZ3$3$FEO()$#]A3<@S L+D@ QO$^F/V/8
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M<T,WFW"TXE5.T\^R^A8)M>=?8W _E*"!GEV_1' QRY;'^I\1VO\ 2=_NF1Y
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MN6$D#'L82'+AC^I(+Y\KY<D$ANG/=AX1R;GRCDX(4]OC_#EN0 QD0\99A['
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MY$XGG[]>?=C+V- P2M6N1@^P]/K[$L[L0<$DN,MTPGGGRPO=[?<'WY;ARPD
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M8PB-YY_#[\.[Z8\N^-MQX./%:X<GPZZS%Q_^'EP[F(   ,/R]R0&X??]%/\
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M,'@!N'VIL _Q#LC@$VA;+$-%S1$(#CL(BXR ">288@.OGG-/Z4S+_G"L'_\
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M!)R<$N3^$#&W+@8((<?5P >[#3DW[]_,XR)]/W,P9C^38R0&( B=MH+,,'+
MGC)8L6);L>XQD .=S$@LY[^>>V.[AY>_MW<.[!$6VL 7';..7&<.[D$D@,Q$
M3.Q-N/,]DX[2"*$KD602%::%R '>= S 8'!<=CZL#TPQ:G3#%:5\_P +*V$.
M#(=R,DIY.>"VT$.<$N'.T88<\_?X:WU&2YP22"'=FVM@$8A!)(A>+  <@MTP
MY^N!V#9); SY0#ZC:68?,20.[A@7///SPC?\^>>ZR[$\1/S^$@Y(+C \WTP
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M0Y[?TB1VAR&'#AB 3"6X/'V:J\]POP':(FY/A[)Q\5C]TDWF9O8;M=21 V2
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M.?CEN(RT,,(#,6,(R0^,[0W!9^'W#IS[^[P^^^(XZ\]MN=^$!$0. X(R,M$
MW(AVM!"/PN'/H29PP$EQS$7 .XD!CG+,W+ &&(D@\@'IAN[>>[X^6$&A!9V
M>(D PEWY?R]@P<@>4@;1"!''=WQY_C],(YN-./;W;H&N'""P<8+L-NX9#&'R
ML[N7/?<<$X$\>?PPY'/"W.[,AHCDF%B!NA#@&$<18'RN26[;6[=.>?K\L,8A
MPSAR6(#^7ZNVYSDL7 (X+%NH.FL<=--^HY]Q:WC[M_?&G?YX98@CS ,S$DDA
MW[0D@8^@B')<D]/AV\Z<S& W\D>^_/?A X( R-P]&8EN#N(8@DG@!Q@MU.!Y
MY]V$1"SP]HG#.W9SN/E^4@!X003Q%P&&$"\19P&?:X+B(,(O-M)YPW(+#:"
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MTJFI"N6Q!'48/8)88X)9FD3$D$4P".9!"8)0CF/%\K D3M#CH)T.F$=WF,=
M:I6$>*_+_P! JO\ N'4;:>/N/TP"2=.,:C7SP?I2L-G^/P-_^SZK_N/3;3Q]
MQ^F$'ASR<'Z4K#P?C\MCP?<*JW_^CC]_3;3Q]Q^F$$Z8/TI6&&>OP!_6GU;_
M '#'[^FVGC[C],(/D8\</]*5AES\?EXY_8*K_N/3;3Q]Q^F$$<]L?&V$-4K#
M/%?@]/[GU7_;[@WK_4?0]-M/'W'Z801X?/#_ $I6'VK\!;ED%5+?0LAP?IS@
M^AZ;2>/N/TQ$<\\G=A?I3L+CX_ X#_W/JW'^@?\ NX]>FTGC[C],3!X;X\>'
M?@_2E8>/X?@S_P"#ZK_N&'[ \C(QTVT\?<?IA!X=G/SX;\/]*-B9_AZ#!8_P
M?5N?] Z;:>/N/TP@_$^4S\#A?I3L+_G!+_T"J_[CTVT\?<?IALGAV>?'AKA_
MI1L,_P#'\O\ T"J_ZOV'/&6X[]-M/'W'Z80=.>=T<;:X/TI6'_E^7_H%5^G_
M $'ZC^L=-M/'W'Z81\_&-8X^&.\MU M"GRT,U96(),NHHY:]%$4=1C]LDFQQ
MRY<YI:2,RQ%'+CAV31!,&US  02VDVOK<:]V$'Y<G3'1_2E8?^7X/S^'U9NW
M?W!NXZ;:>/N/TP@GRG4<8^-L+]*=AX_A^#.1_!]6[<_X!C]_3;3Q]Q^F$'3A
M;4<_3?@_2E8?^7Y>/5!51W;_ !'UZ;:>/N/TQ&#]*5A_Y?@_]'U7T?'[!G![
M=-M/'W'Z88?Z4K#_ ,OR^'_F%5X[_P" ]GSZ=^FVGC[C],3!YY_#"_2E8?\
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M/N^O,'&P-_VA"@D52*M2H4"E3.22%$:9= )BA/#+CG2Q!$E$T>SAFRR8HH!
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MJT;O$D;](DZ"=.-KBX+9N3+V_6^0_P#!2\,V21^H <@^O';N$'^Z=^X^7NQ
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M9*MVG*:M4IOMZC4YZ*E4U(FG5&HS@)JU;'+B4JYHWSID<0!-"UO.D*<4XZH
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M%I0([#($FUP<>\--=0*U>=F4>OK5,<A8IA4IUL,H[)$2E"JG))DZ4(HB8(%
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M.,L<E@7>($;7VLSD$Q N2Y\K[K^&'AS]W.[#?DDF$AR8HG#;68%W[.W)<C&
M.IYYYX^#=Q^?RO@!'FQR0P!B.'W8A!!.?,,N22  1$ [O##  T0<;HMP8.S.
M<'YB2 "P(B)R,ABS"_//N\9W8_,A<3?>"NLQ(J]2R^"ZZ?\ D/\ VN,9Z_-3
M,R/M/,; _KU7VZ5#D&!:18;Y(T@6^7:B>O>O_NSD=Q6H;QON3N )$SKJ _\
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MIBL]*YK,TD37I2$UK7%;:VV84\N:I1JKO5QSZY5XZO5957H_QN.G4VE46F4
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M'#GFW/'#&<)#^9R27QZ@$ 8 (;=C.2XR >F&,0^,.QS"X=@W=B82Q/U/!.T
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ML/EIV:_7X\<!\L/8N ""3N<$< [F8X ."'W$%W8;^;_/\<(LY,41Y+EV'YD
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M" [Y88Q+'CMW!'Y$,&S%ALL&;:V.F'//W8R&/*1N B !Y+ <@#<VUR2'R0
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M+D0KOV^"!?*%,BW&'VT\1[0,,H-26RVIM+R33J0Z'/T2EN!*%020HH 5[<+
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M"YRYS <?0 'TVB(],,$*54(1^RJ2(6((DS7P0P!8Q0L-P<#(8-F(].;\\^[
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M1JCGW52#@C]3-R,EB1"[@=F(S$/R8</(Z\.=< 2*APFGOR-TF8,D@@9A(&T
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M@!WQPQ(<,QZCRY-CWVWW&XVQ'CVS[_+"]T5L $Z@&$$-[*8W#DF$PD;B6V\
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M3Y <@EH3@@=WCSPPXVCA[K\V^6(KM6:$^^1@M$2\N2Q',)+2H@,-DQ;3G,)
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M8;]-VOQ[?EC'+$OP!$#@F$Y9P&,78-Y0Y'+Q&)]\=W=SX3&'AO[>TQX_AC(
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M],,-G+ GG!+N'A( +@G#.P.7Y=X@P\NWPN==//SQC\O)!(PP!=G!/(:+$)
MSB)C@@-.[W##&0#0B$EG#8+$ ^5F(A),4)#9)[L<'IA/,=W/GVX;@Y#D#$+<
M$F(.0.<.,$,7),,1/F:X7N9OKN_'MM?PG  "!W(+/$3EFP1D\\Q$D@&'Y<;6
M'=Y\.[DZ8?#9;(#;F&(LD,,LQR>,.&X<\/+GX88QR(0&;(.?J(F $0;#0L[@
MDPYB8 .>>?EASSS\< ^; Y.79F X&2"" X'T())(B+GAISW'#O\ *_#P^HU
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MYCGGGWZ>AXR8 . 0<&&$@ =GP[/P2X(<_2(=-_/.^WC@;;K<[M_A]83=HFW
M^4DEA^;ENP!<L0W <]1[[:_AQ[!AW1Y3S[^[#;/)P"_=P3\H9@PA)^G<<9G#
MGGGRPMS#<SEV_J9\LS.,_P!$NX,0</G?# !N;D 0N-P+N80!M]/F8@@D@ <%
MBPY]_/C@,(]"Y)+.V21"#@L0,$/"SER0QZ<\</+7F3Y=V%E^"^W(\L0 )P[Y
MX#PL(>2YSTPP8+@D.W.V$.6=G;!9V&7A!_(L,/AA@$@L6Q@AG/,.&&YL88,
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M?V[A'#P%]!Y +</"'X!\K$8>)BYR1$Y+DAHBS]1K]_-O&_9A].9\-UHPNX)
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MJJF]Y,/+-TFW $B"J# (O@1EV;D$AVAY[ =@ 6(R003AW R9O-H)@Z^9X=A
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MMO:>IVJM6?L*J6V7):34&F9+VSU@9;!"<6E;GVG,RX)9C_0M D\S ?I#,]\
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M%=%OT2Y*;[3X?7Z33ZRB$Z$03@EJ224LD0SH!%$()T,N=##-@$40AF"*$11
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(,'3#!TPQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g819343g94r84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g819343g94r84.jpg
M_]C_X0Q717AI9@  34T *@    @ # $   ,    ! ,T   $!  ,    ! #
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  ,   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ .8:0
M   G$  YAI   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,#HP-3HQ,2 R,#HT-3HT,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   #7H , !     $    Z          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MK_XK>A?\7F?]16EG_P#BQZ7_ .%LC_OB75?_ !6]"_XO,_ZBM+/_ /%CTO\
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M]1K'@$0X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-2;'1 \-4<)0        IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .]E'H  @ ! [V4>@ "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M               Z    UP    8 9P Y #0 <@ X #0    !
M              $              -<    Z                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<    Z     %)G:'1L;VYG    UP
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    .@    !29VAT;&]N9P   -<    #=7)L5$585     $
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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MQ &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M:"Y3&469H"^J&IA:FJ,OG#Z1+3RY:@;@QK[]U[J^3W[KW5*GPG_[>@?S&_\
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MMQCF;M29VB93(SV<::H1$I"E[M0:35723W X-[CFOF2WB^J%K9LBG4\=) =
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M@-L*GH\)@LAG\'UC_"^X\QM'$;?[9VC5X*HW?D-]9W:5-F=T;5[ES%%D\RF
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MTU)1T=,D=/2TM/$@5(T5410   /9!)))+(\LKEI&))))))/$DGB3YD]+
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?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
